Profile data is unavailable for this security.
About the company
TMS Co Ltd is a Japan-based company mainly engaged in the research, development, manufacture and marketing of pharmaceuticals. The Company conducts research and development of drug candidate substances based on the research and development results of academia and other research institutions. The current pipeline consists of drug candidates targeting soluble epoxide hydrolase (sEH), one of the enzymes in the human body. sEH inhibition has been shown to provide anti-inflammatory effects and the Company is developing sEH inhibitors for a variety of inflammatory diseases. The lead pipeline, TMS-007, has an anti-inflammatory effect by inhibiting sEH and a thrombolytic effect by acting on plasminogen, and will be clinically developed for acute cerebral infarction. TMS-008, a follow-on product in the pipeline, is being developed for various inflammatory diseases and is currently undergoing pre-clinical studies.
- Revenue in JPY (TTM)0.00
- Net income in JPY-960.04m
- Incorporated2005
- Employees14.00
- LocationTMS Co Ltd5F, Sekiguchi Bldg., 1-23-3, Miya-machiFUCHU-SHI 183-0055JapanJPN
- Phone+81 423065078
- Fax+81 423065078
- Websitehttps://www.tms-japan.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Symbio Pharmaceuticals Ltd | 4.64bn | -2.74bn | 7.16bn | 109.00 | -- | 0.9976 | -- | 1.54 | -66.88 | -66.88 | 113.80 | 156.38 | 0.5439 | 2.76 | 5.14 | 42,594,130.00 | -32.15 | -19.18 | -35.33 | -23.62 | 78.38 | 65.84 | -59.12 | -24.32 | 10.43 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Veritas In Silico Inc | -100.00bn | -100.00bn | 7.20bn | 15.00 | -- | 3.05 | -- | -- | -- | -- | -- | 363.52 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 40.94 | -- | -- | -- | 101.54 | -- | 123.38 | -- | -- | -- |
| Carna Biosciences, Inc. | 1.63bn | -1.15bn | 7.46bn | 67.00 | -- | 1.92 | -- | 4.59 | -69.84 | -69.84 | 96.78 | 226.16 | 0.3774 | 1.36 | 3.35 | 24,267,000.00 | -26.76 | -14.45 | -29.55 | -16.95 | 89.22 | 90.59 | -70.91 | -35.42 | 10.78 | -312.97 | 0.0451 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 7.70bn | 157.00 | -- | 2.42 | -- | -- | -- | -- | -- | 634.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.15 | -- | 0.4102 | -- | 20.16 | -- | 41.20 | -- | -- | -- |
| Wakamoto Pharmaceutical Co Ltd | 7.98bn | -177.67m | 8.33bn | 292.00 | -- | 0.7089 | 35.80 | 1.04 | -5.12 | -5.12 | 229.89 | 337.15 | 0.525 | 2.08 | 2.88 | 27,324,600.00 | -1.17 | -2.58 | -1.34 | -3.00 | 46.98 | 53.08 | -2.23 | -4.33 | 3.45 | -- | 0.0085 | -- | 3.31 | -4.50 | -42.04 | 1.88 | -17.49 | 0.00 |
| CanBas Co Ltd (Parent) | 0.00 | -1.09bn | 8.76bn | 12.00 | -- | 2.93 | -- | -- | -64.47 | -64.47 | 0.00 | 166.10 | 0.00 | -- | -- | 0.00 | -43.91 | -65.86 | -45.99 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| TMS Co Ltd | 0.00 | -960.04m | 9.67bn | 14.00 | -- | 2.80 | -- | -- | -25.89 | -25.89 | 0.00 | 85.77 | 0.00 | -- | -- | -- | -26.14 | -- | -26.78 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -11.51 | -- | -- | -- |
| Tsubota Laboratory Inc | 673.53m | -641.32m | 9.82bn | 10.00 | -- | 7.18 | -- | 14.58 | -25.15 | -25.15 | 26.42 | 53.45 | 0.2711 | 2.04 | 37.74 | -- | -25.82 | -- | -36.41 | -- | 3.17 | -- | -95.22 | -- | 2.31 | -489.86 | 0.0788 | -- | -29.45 | -- | -811.14 | -- | -- | -- |
| Linical Co Ltd | 12.52bn | 680.40m | 10.14bn | 759.00 | 13.61 | 1.18 | 8.53 | 0.8102 | 30.12 | 30.12 | 554.28 | 346.38 | 0.7251 | -- | 3.99 | 16,494,230.00 | 3.94 | 4.71 | 6.55 | 7.23 | 33.10 | 31.60 | 5.43 | 5.98 | -- | 17,809.03 | 0.2793 | 45.36 | 8.32 | 6.55 | 27.06 | -4.97 | -33.01 | 4.94 |
| AnGes Inc | 249.94m | -6.35bn | 10.35bn | 145.00 | -- | 0.3696 | -- | 41.42 | -32.62 | -32.62 | 1.29 | 124.45 | 0.0077 | 0.0862 | 4.77 | 1,723,752.00 | -19.47 | -28.50 | -23.06 | -33.14 | 39.85 | 39.42 | -2,540.59 | -6,726.82 | 0.9124 | -- | 0.0139 | -- | 128.13 | -24.17 | 49.45 | -- | 12.11 | -- |
| 3-D Matrix Ltd | 3.74bn | -1.06bn | 10.69bn | 108.00 | -- | 16.91 | -- | 2.86 | -14.90 | -14.90 | 54.06 | 7.74 | 0.6653 | 0.4654 | 5.19 | 34,630,130.00 | -18.91 | -57.69 | -23.28 | -77.31 | 64.04 | 40.76 | -28.43 | -205.34 | 2.33 | -- | 0.8717 | -- | 53.63 | 58.87 | -29.09 | -- | -7.69 | -- |
| Stella Pharma Corp | 269.49m | -763.75m | 10.93bn | 46.00 | -- | 4.60 | -- | 40.55 | -24.63 | -24.63 | 8.70 | 76.12 | 0.0661 | 0.0508 | 3.98 | -- | -18.74 | -22.50 | -21.00 | -24.83 | 80.63 | -- | -283.40 | -488.65 | 5.52 | -379.39 | 0.2819 | -- | 17.65 | -- | 1.94 | -- | -5.87 | -- |
| KOEI CHEMICAL COMPANY, LIMITED | 19.43bn | 299.18m | 11.14bn | 387.00 | 37.16 | 0.5095 | 4.77 | 0.5733 | 61.17 | 61.17 | 3,971.90 | 4,460.94 | 0.4957 | 1.66 | 3.80 | -- | 0.7659 | 3.15 | 0.997 | 3.94 | 27.17 | 25.24 | 1.55 | 5.85 | 0.6907 | 115.66 | 0.3207 | 43.88 | 4.44 | 1.19 | -56.72 | -20.82 | -3.29 | 10.76 |
| Medinet Co Ltd | 711.82m | -1.40bn | 11.54bn | 98.00 | -- | 2.07 | -- | 16.21 | -6.00 | -6.00 | 3.03 | 21.73 | 0.124 | 11.34 | 3.78 | 7,263,510.00 | -24.31 | -21.05 | -25.48 | -22.47 | 15.25 | 28.75 | -196.06 | -135.40 | 20.08 | -- | 0.00 | -- | 4.40 | -7.90 | -14.66 | -- | -17.67 | -- |
| ReproCell Inc | 2.43bn | -31.42m | 11.64bn | 92.00 | -- | 1.39 | 153.32 | 4.79 | -0.3465 | -0.3465 | 28.34 | 93.45 | 0.2788 | 5.41 | 5.60 | -- | -0.3609 | -7.35 | -0.3932 | -8.00 | 46.19 | 39.83 | -1.29 | -27.16 | 10.54 | -- | -- | -- | -17.83 | 17.39 | 89.71 | -- | 13.27 | -- |
Data as of May 17 2024. Currency figures normalised to TMS Co Ltd's reporting currency: Japanese Yen JPY
9.12%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RTW Investments LPas of 31 Jan 2024 | 3.61m | 8.95% |
| Simplex Asset Management Co., Ltd.as of 04 Apr 2024 | 65.00k | 0.16% |
Data from 31 Dec 2023 - 09 May 2024Source: FactSet Research Systems Inc.
